NEW YORK (GenomeWeb) – Following Meridian Bioscience's preliminary fiscal second quarter revenues that fell short of the analysts' average estimate, investment bank Canaccord Genuity today downgraded the company's shares to a Sell rating from a previous Hold rating.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.